The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cell analysis market reached a value of US$ 16.4 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 7.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cell analysis refers to an umbrella term for a wide variety of technologies that are utilized to study genetic and phenotypical characteristics of a cell. Its objective is to gain insights into the mechanisms of cellular functionality that requires an understanding of the cellular components, such as the DNA, RNA, protein content and cellular metabolites. Cell analysis is typically done to understand population heterogeneity, identifying minority sub-populations of interest, as well as discovering unique characteristics of individual cells. It further aids in gene and protein identification, and epigenomics, as well as understanding the factors that underlie cell health, proliferation and death.
Cell analysis is utilized across academic and research laboratories, hospitals, and biotechnology and pharmaceutical, for studying stem cells, immunology, neurology, non-invasive prenatal diagnosis and in-vitro fertilization. Furthermore, the rising prevalence of chronic diseases, along with the development of advanced therapies for the treatment of cancer, are encouraging technological advancements in cell analysis. For instance, Fluidigm Corporation, a US-based company, announced the introduction of a REAP-seq (RNA expression and protein sequencing) that will help researchers to understand the mechanisms of cancer progression and immune response. The increasing investments by governments of several nations in extensive research and development (R&D) activities in the life science sector are acting as another major growth-inducing factor. Other factors, such as the rapid expansion of the biopharmaceutical and biotechnological companies and significant growth in the healthcare industry, are expected to further create a positive outlook for the market.
Breakup by Product:
Breakup by Analysis Type:
Breakup by Techniques:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies Inc., BD Biosciences, Bio-RAD Laboratories Inc., Danaher Corporation, Illumina Inc., Merck KGaA, Miltenyi Biotec, Olympus Corporation, PerkinElmer Inc., Promega Corporation, Sysmex Corporation, Thermo Fisher Scientific, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Analysis Typel, Techniques, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., BD Biosciences, Bio-RAD Laboratories Inc., Danaher Corporation, Illumina Inc., Merck KGaA, Miltenyi Biotec, Olympus Corporation, PerkinElmer Inc., Promega Corporation, Sysmex Corporation and Thermo Fisher Scientific|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at